On May 4, Axinn partner Chad Landmon and associate Gabriella McIntyre spoke on a virtual panel entitled, "Subtle Defiance: FDA’s Catalyst Response and Strategies for Challenging FDA Decisions" at the Food and Drug Law Institute's Law Over Lunch series.

Click here for more information.